🚀 VC round data is live in beta, check it out!
Alumis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alumis and similar public comparables like J.B. Chemicals & Pharma, NewAmsterdam Pharma, CR Pharmaceutical, Legend Biotech and more.
Alumis Overview
About Alumis
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
Founded
2021
HQ
Employees
170
Website
Sectors
Financials (LTM)
EV
$3B
Alumis Financials
Alumis reported last 12-month revenue of $21M and negative EBITDA of ($271M).
In the same LTM period, Alumis generated $17M in gross profit, ($271M) in EBITDA losses, and had net loss of ($283M).
Revenue (LTM)
Alumis P&L
In the most recent fiscal year, Alumis reported revenue of — and EBITDA of ($291M).
Alumis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $21M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $17M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($271M) | XXX | ($291M) | XXX | XXX | XXX |
| EBITDA Margin | (1317%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (2191%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($283M) | XXX | ($294M) | XXX | XXX | XXX |
| Net Margin | (1376%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alumis Stock Performance
Alumis has current market cap of $4B, and enterprise value of $3B.
Market Cap Evolution
Alumis' stock price is $28.87.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $4B | 0.0% | XXX | XXX | XXX | $-2.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlumis Valuation Multiples
Alumis trades at 158.6x EV/Revenue multiple, and (12.0x) EV/EBITDA.
EV / Revenue (LTM)
Alumis Financial Valuation Multiples
As of March 21, 2026, Alumis has market cap of $4B and EV of $3B.
Equity research analysts estimate Alumis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alumis has a P/E ratio of (12.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 158.6x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (12.0x) | XXX | (11.2x) | XXX | XXX | XXX |
| EV/EBIT | (7.2x) | XXX | (10.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 188.8x | XXX | — | XXX | XXX | XXX |
| P/E | (12.7x) | XXX | (12.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (12.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alumis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alumis Margins & Growth Rates
Alumis' revenue in the last 12 month declined by (40%).
Alumis' revenue per employee in the last FY averaged $0.1M.
Alumis' rule of 40 is (1357%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alumis' rule of X is (1417%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alumis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (40%) | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (1317%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | (16%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (1357%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (1417%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 438% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1845% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alumis Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| J.B. Chemicals & Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| NewAmsterdam Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| CR Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Legend Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Kiniksa Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alumis M&A Activity
Alumis acquired XXX companies to date.
Last acquisition by Alumis was on XXXXXXXX, XXXXX. Alumis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alumis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlumis Investment Activity
Alumis invested in XXX companies to date.
Alumis made its latest investment on XXXXXXXX, XXXXX. Alumis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alumis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alumis
| When was Alumis founded? | Alumis was founded in 2021. |
| Where is Alumis headquartered? | Alumis is headquartered in United States. |
| How many employees does Alumis have? | As of today, Alumis has over 170 employees. |
| Who is the CEO of Alumis? | Alumis' CEO is Martin Babler. |
| Is Alumis publicly listed? | Yes, Alumis is a public company listed on Nasdaq. |
| What is the stock symbol of Alumis? | Alumis trades under ALMS ticker. |
| When did Alumis go public? | Alumis went public in 2024. |
| Who are competitors of Alumis? | Alumis main competitors are J.B. Chemicals & Pharma, NewAmsterdam Pharma, CR Pharmaceutical, Legend Biotech. |
| What is the current market cap of Alumis? | Alumis' current market cap is $4B. |
| What is the current revenue of Alumis? | Alumis' last 12 months revenue is $21M. |
| What is the current revenue growth of Alumis? | Alumis revenue growth (NTM/LTM) is (40%). |
| What is the current EV/Revenue multiple of Alumis? | Current revenue multiple of Alumis is 158.6x. |
| Is Alumis profitable? | No, Alumis is not profitable. |
| What is the current EBITDA of Alumis? | Alumis has negative EBITDA and is not profitable. |
| What is Alumis' EBITDA margin? | Alumis' last 12 months EBITDA margin is (1317%). |
| What is the current EV/EBITDA multiple of Alumis? | Current EBITDA multiple of Alumis is (12.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.